Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star Therapeutics Inc., (NASDAQ: FSTX), and Japan-based Takeda Pharmaceutical Co., Ltd. The agreement facilitates the utilization of F-star’s proprietary wholly human Fcab and tetravalent mAb2 platforms to develop next-generation multi-specific immunotherapies targeting cancer.
Joint Research and Development Efforts
According to the agreement, F-star and Takeda will collaborate on the research and development of new Fcab domains targeting undisclosed immune oncology targets. Takeda will secure an exclusive global license to research, develop, and commercialize antibodies containing Fcab structures generated through this collaboration. Meanwhile, F-star retains the right to research, develop, and commercialize antibodies containing several other Fcab structures.
Financial Terms and Milestones
F-star is set to receive an undisclosed advance payment and research funding during the cooperation period. Additionally, the company is eligible for potential milestone payments of up to USD 1 billion and annual net sales-based royalties, highlighting the significant investment and potential returns associated with this partnership.
Building on Previous Collaborations
This latest agreement builds on two previous licensing deals struck between the two companies in July 2022 and March 2023, demonstrating a continued commitment to advancing immunotherapeutic options for cancer treatment.
